Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,412.00
Bid: 12,412.00
Ask: 12,416.00
Change: 14.00 (0.11%)
Spread: 4.00 (0.032%)
Open: 12,432.00
High: 12,482.00
Low: 12,400.00
Prev. Close: 12,398.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

G7 to donate 1 billion COVID-19 vaccine doses to poorer countries

Thu, 10th Jun 2021 22:30

By Kate Holton

CARBIS BAY, England, June 10 (Reuters) - British Prime
Minister Boris Johnson expects the Group of Seven to agree to
donate 1 billion COVID-19 vaccine doses to poorer countries
during its summit starting on Friday, and help innoculate the
world by the end of next year.

Just hours after U.S. President Joe Biden vowed to
supercharge the battle against the coronavirus with a donation
of 500 million Pfizer shots, Johnson said Britain would
give at least 100 million surplus vaccines to the poorest
nations.

Johnson has already called on G7 leaders to commit to
vaccinate the entire world by the end of 2022 and the group is
expected to pledge 1 billion doses during its three-day summit
in the English seaside resort of Carbis Bay.

Some campaign groups condemned the plan as a drop in the
ocean, with Oxfam estimating that nearly 4 billion people will
depend on COVAX for vaccines, the programme that distributes
COVID-19 shots to low and middle income countries.

"As a result of the success of the UK's vaccine programme we
are now in a position to share some of our surplus doses with
those who need them," Johnson will say on Friday, according to
excerpts of the announcement released by his office.

"In doing so we will take a massive step towards beating
this pandemic for good."

COVID-19 has killed around 3.9 million people and ripped
through the global economy, with infections reported in more
than 210 countries and territories since the first cases were
identified in China in December 2019.

While scientists have brought vaccines to market at
breakneck speeds - Britain has given a first dose to 77% of its
adult population and the United States 64% - they say the
pandemic will only end once all countries have been vaccinated.

With a global population nearing 8 billion and most people
needing two doses, if not booster shots to tackle variants as
well, campaigners said the commitments marked a start but world
leaders needed to go much further, and much faster.

"The G7's aim to provide 1 billion doses should be seen as
an absolute minimum, and the timeframe needs to speed up," said
Lis Wallace at anti-poverty campaign group ONE.

"We're in a race with this virus and the longer it's in the
lead the greater the risk of new, more dangerous variants
undermining global progress."

Of the 100 million British shots, 80 million will go to the
COVAX programme led by the World Health Organization (WHO) and
the rest will be shared bilaterally with countries in need.

Johnson echoed Biden in calling on his fellow leaders to
make similar pledges and for pharmaceutical companies to adopt
the Oxford-AstraZeneca model of providing vaccines at cost for
the duration of the pandemic.

Leaving poorer countries to deal with the pandemic alone
risks allowing the virus to further mutate and evade vaccines.
Charities have also said that logistical support will be needed
to help administer large numbers of vaccines in poorer
countries.

The British doses will be drawn from the stock it has
already procured for its domestic programme, and will come from
suppliers Oxford-AstraZeneca, Pfizer-BioNTech,
Janssen, Moderna and others.

(Reporting by Kate Holton; editing by Guy Faulconbridge and
Grant McCool)

More News
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more
2 Jan 2024 11:00

Weight-loss drugs: Who, and what, are they good for?

Jan 2 (Reuters) - Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to address record obesity rates.

Read more
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more
2 Jan 2024 08:48

LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs

(Alliance News) - Stock prices in London opened mostly up on Tuesday, the first day of trading in 2024, reacting to slightly improved factory activity in China, with more manufacturing PMIs from major economies due.

Read more
2 Jan 2024 08:26

AstraZeneca and Sanofi received approval in China for RSV antibody

(Alliance News) - AstraZeneca PLC and Sanofi SA's long-acting monoclonal antibody Beyfortus received approval for use in China to prevent respiratory syncytial virus disease, Astra said on Tuesday.

Read more
2 Jan 2024 07:57

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

Read more
27 Dec 2023 17:04

Rate-cut optimism, autos push UK stocks higher

FTSE 100 up 0.4%, FTSE 250 adds 0.5%

*

Read more
27 Dec 2023 17:02

LONDON MARKET CLOSE: Stocks start week higher as 2024 draws to close

(Alliance News) - Equities in London kicked off an abbreviated trading week with gains on Wednesday, on continued US interest rate optimism at the end of 2024.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.